Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
Manca P, Corallo S, Randon G, Lonardi S, Cremolini C, Rimassa L, Bergamo F, Antoniotti C, Smiroldo V, Zaniboni A, Murialdo R, Tampellini M, Tomasello G, Clavarezza M, Racca P, Antista M, Raimondi A, Prisciandaro M, Pagani F, Palermo F, Greco FG, Vaiani M, Di Bartolomeo M, de Braud F, Calareso G, Morano F, Pietrantonio F. Manca P, et al. Among authors: di bartolomeo m. Eur J Cancer. 2021 Feb;144:31-40. doi: 10.1016/j.ejca.2020.11.017. Epub 2020 Dec 13. Eur J Cancer. 2021. PMID: 33321462 Free article.
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R; Italian Trials in Medical Oncology (I.T.M.O.) Group. Bajetta E, et al. Among authors: di bartolomeo m. Cancer. 2004 Jan 15;100(2):279-87. doi: 10.1002/cncr.11910. Cancer. 2004. PMID: 14716761 Free article. Clinical Trial.
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Bajetta E, Di Bartolomeo M, Buzzoni R, Ferrario E, Dotti KF, Mariani L, Bajetta R, Gevorgyan A, Venturino P, Galassi M. Bajetta E, et al. Among authors: di bartolomeo m. Cancer Chemother Pharmacol. 2009 Jun;64(1):67-72. doi: 10.1007/s00280-008-0852-1. Epub 2008 Oct 21. Cancer Chemother Pharmacol. 2009. PMID: 18936940 Clinical Trial.
A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.
Wolff RA, Fuchs M, Di Bartolomeo M, Hossain AM, Stoffregen C, Nicol S, Heinemann V. Wolff RA, et al. Among authors: di bartolomeo m. Cancer. 2012 Sep 1;118(17):4132-8. doi: 10.1002/cncr.26692. Epub 2011 Dec 27. Cancer. 2012. PMID: 22213153 Free article. Clinical Trial.
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen.
Pietrantonio F, Biondani P, de Braud F, Pellegrinelli A, Bianchini G, Perrone F, Formisano B, Di Bartolomeo M. Pietrantonio F, et al. Among authors: di bartolomeo m. Transl Oncol. 2012 Jun;5(3):155-9. doi: 10.1596/tlo.12151. Epub 2012 Jun 1. Transl Oncol. 2012. PMID: 22741034 Free PMC article.
254 results